Centre for Social Research in Health, UNSW Sydney, Sydney, Australia.
Health Soc Care Community. 2022 Nov;30(6):e3775-e3788. doi: 10.1111/hsc.14066. Epub 2022 Oct 19.
Ageing with a chronic hepatitis B (HBV) or hepatitis C (HCV) infection is an emerging public health priority. For people living with chronic viral hepatitis, their disease progression into old age is both underpinned by their existing blood borne virus and the potential emergence of other infectious and non-infectious conditions. These twinned pathways bring additional challenges to the care and support for people as they near end of life. This scoping review sought to examine what is known about the experiences of the end-of-life phase of an increasing population ageing with HBV and HCV in studies conducted in high-income settings and published in peer reviewed literature (2010-2021). In interpreting this literature, we found that challenges in determining the end-of life phase for people with lived experience of HBV or HCV are exacerbated by the conflation of aetiologies into a singular diagnosis of end-stage liver disease. Studies overwhelmingly reported the clinical aspects of end-of-life care (i.e. prognosis assessment and symptom management) with less attention paid to educative aspects (i.e. advance care directives and surrogate decision makers, discussion of treatment options and determining goals of care). Psychosocial interventions (i.e. quality of life beyond symptom management, including emotional/spiritual support and family and bereavement support) received limited attention in the literature, though there was some recognition that psychosocial interventions should be part of end-of-life care provision. Given the focus on the prominent disease presentation of liver cirrhosis and/or end-stage liver disease, the social and cultural dimensions of these infections have received less attention in the literature on end-of-life in the context of chronic viral hepatitis.
随着慢性乙型肝炎 (HBV) 或丙型肝炎 (HCV) 感染患者年龄的增长,这一问题已成为新的公共卫生重点。对于慢性病毒性肝炎患者来说,其疾病向老年期的发展既受到现有血源性病毒的影响,也受到其他传染性和非传染性疾病的潜在影响。这两条途径给接近生命末期的患者的护理和支持带来了额外的挑战。本范围综述旨在研究在高收入环境中进行的同行评议文献中,针对 HBV 和 HCV 感染人数不断增加的人群老龄化末期阶段的经验的研究中,了解到哪些内容(2010-2021 年)。在解释这些文献时,我们发现,由于将病因学合并为终末期肝病的单一诊断,导致确定 HBV 或 HCV 患者生命末期阶段的挑战更加复杂。研究报告压倒性地集中在生命末期护理的临床方面(即预后评估和症状管理),而对教育方面(即预先护理指令和替代决策者、治疗方案的讨论以及确定护理目标)关注较少。心理社会干预(即症状管理之外的生活质量,包括情感/精神支持以及家庭和丧亲支持)在文献中受到的关注有限,尽管人们已经认识到心理社会干预应该是生命末期护理的一部分。鉴于重点关注肝硬化和/或终末期肝病这一突出疾病表现,这些感染的社会和文化层面在慢性病毒性肝炎的生命末期文献中受到的关注较少。